Lisa Claude
A5081908094- Blood Pressure and Hypertension Studies
- Hemodynamic Monitoring and Therapy
- Heart Rate Variability and Autonomic Control
- Cardiovascular Health and Disease Prevention
- Renal and Vascular Pathologies
- Renin-Angiotensin System Studies
- Vascular anomalies and interventions
- Heart rate and cardiovascular health
- Hormonal Regulation and Hypertension
- Advanced MRI Techniques and Applications
Tableau Software (United States)
2020
Importance Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and is resistant treatment. Objective To study the efficacy safety of without confounding influence antihypertensive medications hypertension. Design, Setting, Participants Sham-controlled, randomized clinical trial outcome assessors blinded treatment assignment was conducted between January 14, 2019, March 25, 2022, at 37...
Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP) in patients with uncontrolled hypertension (HTN). Establishing the magnitude and consistency of uRDN effect across HTN spectrum is clinically important.
Importance Although early trials of endovascular renal denervation (RDN) for patients with resistant hypertension (RHTN) reported inconsistent results, ultrasound RDN (uRDN) was found to decrease blood pressure (BP) vs sham at 2 months in RHTN taking stable background medications the Study ReCor Medical Paradise System Clinical Hypertension (RADIANCE-HTN TRIO) trial. Objectives To report prespecified analysis persistence BP effects and safety uRDN 6 conjunction escalating antihypertensive...
BACKGROUND: The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, TRIO, and RADIANCE II Stage trials independently met their primary end point a greater reduction daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound renal denervation (uRDN) patients with hypertension. To characterize longer-term effectiveness safety uRDN versus sham at 6 months, blinded addition antihypertensive treatments (AHTs), we...
Abstract The blood pressure (BP) lowering response to renal denervation (RDN) remains variable with about one-third of patients not responding ultrasound or radiofrequency RDN. Identification predictors the BP RDN is needed optimize patient selection for this therapy. This a post-hoc analysis RADIANCE-HTN SOLO study. was measured by change in daytime ambulatory systolic (dASBP) at 2 months post procedure. Univariate regression used initially assess potential outcome followed multivariate...
Renal denervation (RDN) is effective in lowering blood pressure (BP) patients with hypertension. The issue remains how to best identify potential responders. Ambulatory BP monitoring may be useful. Baseline nighttime systolic (SBP) ≥136 mm Hg and its variability (SD) ≥12 DENER-HTN trial or 24-hour heart rate ≥73.5 bpm SPYRAL HTN-OFF MED Trial were shown predict the response RDN. We applied these criteria hypertension sham-controlled RADIANCE-HTN SOLO ultrasound RDN at 2 months while...
Objective: The RADIANCE-HTN SOLO trial demonstrated a greater reduction in daytime ambulatory SBP at 2 months by endovascular ultrasound renal denervation than sham procedure. We hypothesized that plasma renin and aldosterone concentrations would be associated with the response to denervation. Methods: Hypertensive patients were randomized ( n = 74) or 72) after 4-week washout of antihypertensive medications. In 53-patient subset, 2-month 6-month concentration measured. Dietary sodium was...